脓毒症相关细胞因子风暴的机制与治疗策略

doi:10.16352/j.issn.1001-6325.2025.02.0263

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (2): 263-267.doi: 10.16352/j.issn.1001-6325.2025.02.0263

脓毒症相关细胞因子风暴的机制与治疗策略

王婷婷, 秦海东^*

南京医科大学附属南京医院急诊科,江苏南京 210006

收稿日期:2024-05-07 修回日期:2024-07-15 出版日期:2025-02-05 发布日期:2025-01-17
通讯作者: ^*qhd1234567890@njmu.edu.cn
基金资助:
南京市医学科技发展计划(YKK22115)

Mechanisms and therapeutic strategies of sepsis-associated cytokine storm

WANG Tingting, QIN Haidong^*

Department of Emergency Medicine, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China

Received:2024-05-07 Revised:2024-07-15 Online:2025-02-05 Published:2025-01-17
Contact: ^*qhd1234567890@njmu.edu.cn

摘要/Abstract

摘要： 脓毒症(sepsis)是临床常见的急危重症之一,死亡率居高不下。细胞因子风暴(CS)作为脓毒症的核心病理机制,其免疫系统的持续激活和大量细胞因子的无序释放对患者的组织和器官造成严重损伤,导致全身炎性反应综合征(SIRS)甚至多器官功能障碍综合征(MODS),严重威胁患者健康。因此,本文针对细胞因子风暴在脓毒症中的作用及当前治疗策略进行综述。

关键词: 脓毒症, 细胞因子风暴, 先天免疫, 全身炎性反应综合征, 多器官功能障碍综合征

Abstract: Sepsis is one of the most common critical conditions in clinical practice, with a persistently high mortality rate. As the core pathological mechanism of sepsis, cytokine storm, the continuous activation of the immune system and the disordered release of a large number of cytokines cause severe damage to the patient's tissues and organs, leading to systemic inflammatory response syndrome and even multiple organ dysfunction syndrome, posing a significant threat to patient health. Therefore, this article reviews the role of cytokine storm in sepsis and current therapeutic strategies.

Key words: sepsis, cytokine storm, innate immunity, systemic inflammatory response syndrome, multiple organ dysfunction syndrome

中图分类号:

R363

王婷婷, 秦海东. 脓毒症相关细胞因子风暴的机制与治疗策略[J]. 基础医学与临床, 2025, 45(2): 263-267.

WANG Tingting, QIN Haidong. Mechanisms and therapeutic strategies of sepsis-associated cytokine storm[J]. Basic & Clinical Medicine, 2025, 45(2): 263-267.

参考文献 25

[1]	石丹丹, 蒋素芳, 王茜,等. IL-6反式信号传导通路抑制剂sgp130Fc抑制脓毒症小鼠炎性反应及调节免疫细胞[J]. 基础医学与临床, 2022, 42: 1895-1899.
[2]	Jarczak D, Kluge S, Nierhaus A. Sepsis-pathophysiology and therapeutic concepts[J]. Front Med (Lausanne), 2021, 8: 628302.doi: 10.3389/fmed.2021.628302.
[3]	Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19[J]. Immunity, 2020, 53: 19-25.
[4]	Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications[J]. Int J Mol Sci, 2022, 23.doi: 10.3390/ijms231911740.
[5]	Cui Z, Wang L, Li H, et al. Study on immune status alterations in patients with sepsis[J]. Int Immuno-pharmacol, 2023, 118: 110048.doi: 10.1016/j.intimp.2023.110048.
[6]	Karki R, Kanneganti TD. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19[J]. J Transl Med, 2022, 20: 542.doi: 10.1186/s12967-022-03767-z.
[7]	Orning P, Lien E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity[J]. J Leukoc Biol, 2021, 109: 121-141.
[8]	Malireddi RKS, Gurung P, Kesavardhana S, et al. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease[J]. J Exp Med, 2020, 217.doi: 10.1084/jem.20191644.
[9]	Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes[J]. Cell, 2021, 184: 149-168 e117.
[10]	孙晓丽, 张进进, 宋凤英,等. Tim-3/galectin-9调控脂多糖诱导的人淋巴细胞中Th1/Th2细胞平衡[J]. 基础医学与临床, 2023, 43: 1542-1548.
[11]	Li Z, Feng Y, Zhang S, et al. A multifunctional nanoparticle mitigating cytokine storm by scavenging multiple inflammatory mediators of sepsis[J]. ACS Nano, 2023, 17: 8551-8563.
[12]	Tang H, Qin S, Li Z, et al. Early immune system alterations in patients with septic shock[J]. Front Immunol, 2023, 14: 1126874.doi: 10.3389/fimmu.2023.1126874.
[13]	Darden DB, Bacher R, Brusko MA, et al. Single-cell RNA-seq of human myeloid-derived suppressor cells in late sepsis reveals multiple subsets with jnique transcriptional responses: a pilot study[J]. Shock, 2021, 55: 587-595.
[14]	Darden DB, Kelly LS, Fenner BP, et al. Dysregulated immunity and immunotherapy after sepsis[J]. J Clin Med, 2021, 10.doi: 10.3390/jcm10081742.
[15]	Galvan-Roman JM, Rodriguez-Garcia SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study[J]. J Allergy Clin Immunol, 2021, 147: 72-80 e78.
[16]	Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19[J]. J Clin Invest, 2020, 130: 6409-6416.
[17]	Hwang SJ, Wang JH, Lee J S, et al. Ginseng sprouts attenuate mortality and systemic inflammation by modulating TLR4/NF-kappaB signaling in an LPS-induced mouse model of sepsis[J]. Int J Mol Sci, 2023, 24.doi: 10.3390/ijms24021583.
[18]	Ono Y, Maejima Y, Saito M, et al. TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice[J]. Sci Rep, 2020, 10: 694.doi: 10.1038/s41598-020-57714-3.
[19]	Yang M, Fang JT, Zhang NS, et al. Caspase-1-inhibitor AC-YVAD-CMK inhibits pyroptosis and ameliorates acute kidney injury in a model of sepsis[J]. Biomed Res Int, 2021, 2021: 6636621.doi: 10.1155/2021/6636621.
[20]	Lesnik P, Janc J, Mierzchala-Pasierb M, et al. Interleukin-7 and interleukin-15 as prognostic biomarkers in sepsis and septic shock: correlation with inflammatory markers and mortality[J]. Cytokine, 2023, 169: 156277.doi: 10.1016/j.cyto.2023.156277.
[21]	Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis[J]. Front Immunol, 2023, 14: 1130214.doi: 10.3389/fimmu.2023.1130214.
[22]	Chang C, Hu L, Sun S, et al. Regulatory role of the TLR4/JNK signaling pathway in sepsis-induced myo-cardial dysfunction[J]. Mol Med Rep, 2021, 23.doi: 10.3892/mmr.2021.11973.
[23]	Zhang T, Yu-Jing L, Ma T. Role of regulation of PD-1 and PD-L1 expression in sepsis[J]. Front Immunol, 2023, 14: 1029438.doi: 10.3389/fimmu.2023.1029438.
[24]	Nakamori Y, Park EJ, Shimaoka M. Immune deregulation in sepsis and septic shock: reversing immune paralysis by targeting PD-1/PD-L1 pathway[J]. Front Immunol, 2020, 11: 624279.doi: 10.3389/fimmu.2020.624279.
[25]	Yim D, Lee DE, So Y, et al. Sustainable nanosheet antioxidants for sepsis therapy via scavenging intracellular reactive oxygen and nitrogen species[J]. ACS Nano, 2020, 14: 10324-10336.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	11

	来源	本网站

	次数	11
	比例	100%

摘要

最新录用	在线预览	正式出版

0	0	52

	来源	本网站

	次数	52
	比例	100%

脓毒症相关细胞因子风暴的机制与治疗策略

Mechanisms and therapeutic strategies of sepsis-associated cytokine storm

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	邢雨润, 陈苏颖, 屠金恒, 何伯圣. 肠缺血/再灌注损伤对远端器官功能的影响[J]. 基础医学与临床, 2025, 45(3): 395-398.
[2]	孙晓丽, 张进进, 宋凤英, 黄永莉, 陈立力, 邢颜超. Tim-3/galectin-9调控脂多糖诱导的人淋巴细胞中Th1/Th2细胞平衡[J]. 基础医学与临床, 2023, 43(10): 1542-1548.
[3]	王英臣, 孙立群. 二肽基肽酶Ⅲ在治疗脓毒症中的应用进展[J]. 基础医学与临床, 2023, 43(1): 196-199.
[4]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[5]	匡重伸, 丛竹凯, 吴长毅, 杨宁, 宗亚楠, 郭向阳. 内脂素在脓毒症相关性脏器损伤中的作用及机制研究进展[J]. 基础医学与临床, 2022, 42(8): 1279-1283.
[6]	林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.
[7]	温燕, 林金灿, 黄颖泓, 肖文彪, 张民伟, 林建东. 脓毒症早期BMP-2和BMP-4的变化[J]. 基础医学与临床, 2022, 42(4): 628-632.
[8]	石丹丹, 蒋素芳, 王茜, 赵鹏博, 刘雅. IL-6反式信号传导通路抑制剂sgp130Fc抑制脓毒症小鼠炎性反应及调节免疫细胞[J]. 基础医学与临床, 2022, 42(12): 1895-1899.
[9]	李嘉晋, 刘军, 何松于, 谌浩云. 下调miR-27a减轻脓毒症模型大鼠肺损伤[J]. 基础医学与临床, 2022, 42(11): 1704-1708.
[10]	斯晓燕, 王汉萍, 张力, 王孟昭, 张晓彤. 免疫检查点抑制剂致细胞因子释放综合征1例[J]. 基础医学与临床, 2022, 42(11): 1764-1766.
[11]	王玉龙, 滕文彬, 单跃, 姚刘旭, 何锐, 李玉红, 祝胜美. HIF-1α激动剂或拮抗剂对脓毒症大鼠肠道黏膜通透性的影响[J]. 基础医学与临床, 2021, 41(11): 1618-1623.
[12]	邵瑞飞, 杨艳, 郑志榕, 赵世民, 陈国兵. 肠道菌群和“肠-肺”轴在脓毒症中的作用[J]. 基础医学与临床, 2020, 40(8): 1109-1112.
[13]	何锐, 朱烨柯, 滕文彬, 单跃, 易声华, 祝胜美, 李玉红. 甘油可能通过水通道蛋白3减轻脓毒症小鼠肠黏膜屏障损伤[J]. 基础医学与临床, 2020, 40(5): 655-661.
[14]	文大林, 杜娟, 陈民佳, 孙剑会, 张华才, 张安强, 都定元. 联合检测C反应蛋白和降钙素原在创伤后脓毒症患者早期预警中的作用[J]. 基础医学与临床, 2020, 40(2): 178-181.
[15]	吴铭蒋苇苇高莉莉. 脂氧素A4降低LPS致肥胖大鼠炎性因子的释放[J]. 基础医学与临床, 2018, 38(12): 1749-1752.